Andrés Pizzorno holds a Ph.D. in Microbiology-Immunology and currently works as a postdoctoral researcher at the VirPath Team of the Centre International de Recherche en Infectiologie in Lyon (France). With +10-year research experience in the field of respiratory viruses, antiviral resistance and therapeutics, his research focuses on the study of virus-host interactions at the transcriptomic, molecular and cellular level as the starting point for the development, characterization, pre-clinical and clinical evaluation of innovative host-targeted antiviral approaches. Dr. Pizzorno is author of 26 scientific publications and co-inventor of several patents. He is also co-founder and project manager of Signia Therapeutics SAS.

Back to isirv-AVG Committee